The FDA has approved Cinvanti (Heron), an IV emulsion formulation of the substance P/neurokinin-1 (NK1) receptor antagonist aprepitant, for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Aprepitant is also available in oral capsule and suspension formulations (Emend, and generics), and fosaprepitant, a prodrug of aprepitant, is available in an IV formulation (Emend for injection).

STANDARD TREATMENT — Patients receiving moderately emetogenic chemotherapy are generally treated with dexamethasone (Decadron, and generics) and a 5-HT₃ receptor antagonist such as palonosetron (Aloxi, and generics) for prevention of CINV; those receiving carboplatin-based chemotherapy should also receive a substance P/NK1 receptor antagonist (see Table 1). Most patients treated with ... more      

Would you like to read the rest of this article?  Gain access below.